Prevention / Projects

3rd Health Programme (2014-2020)
Empowering Hospital [Emp-H]
This multicentre project aims to foster health promotion interventions and environments suitable for patients, their families, and health professionals. The strategy is based on the Health Promoting H...
This multicentre project aims to foster health promotion interventions and environments suitable for patients, their families, and health professionals. The strategy is based on the Health Promoting Hospitals (HPH) framework with a strong emphasis on evidence based prevention.
The ultimate goal of this project is achievement of measurable improvements in population health through comprehensive promotion of healthy behaviours in diverse and complementary categories of individuals.
The project would focus on vulnerable patients presenting with acute manifestation of an underlying chronic condition, and on those they have stronger bonds with. Both patients and their families are assumed—in line with theory and evidence—to feel more susceptible to illness and more open to realize

Start date: 01/05/2015 - End date: 30/04/2018

Call: Call for Proposals for Projects 2014
Topic: Prevention
3rd Health Programme (2014-2020)
Social Engagement Framework for Addressing the Chronic-disease-challenge [SEFAC]
SEFAC supports the actions in the European regions, in alignment with national/EU efforts to reduce the burden of major chronic disease and to increase the sustainability of health systems. SEFAC fost...
SEFAC supports the actions in the European regions, in alignment with national/EU efforts to reduce the burden of major chronic disease and to increase the sustainability of health systems. SEFAC fosters the involvement of volunteers in a broad community approach initiated by social and health care. The focus of SEFAC is on positive health, prevention, empowerment and self-management, using group and individual approaches, face-to-face and online, supported by user friendly ICT tools.

Four regions in varied European countries will actively participate as SEFAC pilot sites. Citizens of circa 50 years and older, who have a major chronic disease or who want to prevent chronic disease, and social/health professionals, pharmacists and volunteers will co-create communities for the promotion of health, and prevention and (self) management of chronic diseases.

In 4 pilot regions (Rijeka in Croatia, Treviso in Italy, Rotterdam in the Netherlands, and Cornwall in the UK), a total of 1000 citizens (250 per pilot) will be involved through community meetings. In total 360 participants (90 per pilot) will actively participate in a range of prevention and disease management activities; i.e. a series of group activities in addition to individual (volunteer reinforced) care pathways and the use of ICT tools. Stakeholders in the 4 pilot regions will be trained to implement prevention and self-management activities with help of volunteers using a ‘Social engagement toolkit’.

We will apply the CDC-Framework for Program Evaluation including the perspectives of the end-users (citizens who want to prevent/self-manage chronic disease), as well as social/health care providers, pharmacists, volunteers and other stakeholders; a cost-effectiveness analysis will be performed. Using the learnings of this project, a SEFAC toolbox for implementation in European regions will be developed, including policy briefs providing policy makers and public authorities with key points for action.
Start date: 01/05/2017 - End date: 30/04/2021

Call: Call for Proposals for Projects 2016
Topic: Prevention
3rd Health Programme (2014-2020)
TOBACCO CESSATIION GUIDELINES FOR HIGH RISK GROUPS [TOB-G]
TOB-G project aims to develop and implement an innovative and cost effective approach to prevent chronic diseases related to tobacco dependence. The specialized guidelines for high risks groups will b...
TOB-G project aims to develop and implement an innovative and cost effective approach to prevent chronic diseases related to tobacco dependence. The specialized guidelines for high risks groups will be developed according to ENSP’s evidence based and good practices in tobacco cessation and with ERS TCC scientific material on smoking health hazards. High risk populations are considered those who suffer from cardiovascular diseases, COPD, type 2 diabetes, adolescents & pregnant women.The developed guidelines will contain strategies and recommendations designed to assist health professionals in delivering and supporting effective treatment of dependence on tobacco. Recommendations will be made as a result of scientific reviews and evidence of good practices from scientific groups that will consist of health professionals of different expertise. To monitor the quality of the approach a pilot implementation of the tobacco cessation will be conducting for each group. The assessment of the effectiveness of the tobacco cessation guidelines will be the primary aim of the scientific groups and will be measured by the number of people quitting smoking after the pilot implementation. Since the tobacco cessation guidelines will be addressed to health professionals, the partnership will develop and implement an e-learning training for guidelines use.The project fits perfectly the objectives and priorities of the 3rd Health Programme, as it will assist health professionals to provide guidance and targeted prevention to high risk populations engaged to the unfavourable lifestyle of smoking. Training primary care physicians addresses the lack of specialist doctors in EU and increases access to tobacco cessation specialists. TOB-G project will enhance the overall European capacity in the treatment of tobacco dependence, thus, in the prevention of chronic diseases, through offering smoking cessation tools, appropriately assessed and fitted to the specific needs of high risk groups.
Start date: 01/06/2015 - End date: 30/11/2017

Call: Call for Proposals for Projects 2014
Topic: Prevention
3rd Health Programme (2014-2020)
Joint Action on integrating prevention, testing and linkage to care strategies acros HIV, viral hepatitis, TB and STIs in Europe (INTEGRATE) [INTEGRATE]
The “Joint Action on integrating prevention, testing and link to care strategies across HIV, Viral Hepatitis, TB & STIs in Europe” (INTEGRATE) has the overall objective to increase Integrated earl...
The “Joint Action on integrating prevention, testing and link to care strategies across HIV, Viral Hepatitis, TB & STIs in Europe” (INTEGRATE) has the overall objective to increase Integrated early diagnosis and linkage to prevention and care of HIV, viral hepatitis, TB and STIs in EU Member States by 2020.
A number of tools have been developed to reduce transmission, optimize early diagnosis and linkage to care for one or more of these four diseases. INTEGRATE will map relevant existing tools for cross-linking. A peer-review process will identify which of these tools are complimentary or redundant for other disease(s), and which could be adapted or require further innovation.
HIV, viral hepatitis, TB and STIs are cross-borders public health threats of concern to Europe that affect vulnerable populations disproportionately and require personalised interventions. As multiple dimensional approaches are required to reduce the public health burden, the most optimal profile of approaches that provide additive effects (and that are reasonably cost-effective) should be identified and implemented broadly.
INTEGRATE provides a platform to disseminate and exchange best practice among Member States and facilitate discussions on innovations and emerging issues within the four diseases. In this respect, INTEGRATE is a shared European effort that extends beyond the partners and can create important synergies across European stakeholders, projects and initiatives.
INTEGRATE supports the implementation of the Commission Communication on ‘Combating HIV/AIDS in the European Union and neighboring countries’ and the ‘Action Plan on HIV/AIDS in the EU and neighboring countries’ by ensuring better preparedness across the EU and by identifying innovative evidence-based testing and prevention tools to reduce new cases of HIV, viral hepatitis, TB and STIs in priority groups.
Start date: 01/09/2017 - End date: 31/05/2021

Call: Joint Actions 2016
Topic: Prevention
3rd Health Programme (2014-2020)
European Reference Network for GEnetic TUmour RIsk Syndromes - GENTURIS [ERN GENTURIS]
GENTURIS is a European Reference Network (ERN) for all patients with one of the rare genetic tumour risk syndromes (genturis). These patients are at very high hereditary risk of developing multiple tu...
GENTURIS is a European Reference Network (ERN) for all patients with one of the rare genetic tumour risk syndromes (genturis). These patients are at very high hereditary risk of developing multiple tumours, which are often located in multiple organ systems. In case they are diagnosed with cancer they need different treatment and follow-up as compared to non-hereditary cancers. In addition GENTURIS takes care of the relatives of these patients, for which prevention and early detection of tumours is of great importance too.
WHAT IS OUR MISSION: To inspire hope and contribute to health and well being by organizing and providing the best care to every patient in Europe with a genetic tumour risk syndrome through integrated multidisciplinary healthcare, guidelines, education and research.
WHAT IS OUR DESIRED END-STATE: Striving to be the world’s leader of genetic tumour risk syndromes in patient participation, clinical care, research and education.
The ERN GENTURIS is addressing the following challenges when it comes to the identification, genetic testing, tumour prevention and treatment of patients with genturis: 1) Great majority of genturis patients are not yet identified 2) Large variation in clinical outcomes resulting in impaired prognosis and avoidable costs 3) Guidelines are lacking or implemented insufficiently 4) Almost no patient registries and biobanks 5) Limited research programs 6) Fragmented patient empowerment activities.
There are 4 thematic groups of syndromes: 1: Neurofibromatosis type 1, 2 & Schwannomatosis. 2: Lynch syndrome & polyposis. 3: Hereditary breast & ovarian cancer. 4: Other rare - predominantly malignant - syndromes. This group includes syndromes not covered in the other groups. It is a heterogeneous group with very small numbers of patients that will benefit greatly from a centralized approach. Within the next years not yet covered as well as newly discovered genturis will be included as well.

Start date: 02/03/2017 - End date: 01/03/2022

Call: European Reference Networks
Topic: Prevention